Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Enterprise Value (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Enterprise Value for 4 consecutive years, with -$204.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 40.33% to -$204.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$204.2 million, a N/A change, with the full-year FY2024 number at -$189.3 million, down 9.58% from a year prior.
  • Enterprise Value was -$204.2 million for Q3 2025 at Century Therapeutics, up from -$251.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$92.0 million in Q2 2023 to a low of -$378.8 million in Q2 2022.
  • A 4-year average of -$232.1 million and a median of -$196.4 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 75.72% in 2023, then tumbled 113.58% in 2024.
  • Century Therapeutics' Enterprise Value stood at -$315.5 million in 2022, then soared by 45.25% to -$172.7 million in 2023, then decreased by 9.58% to -$189.3 million in 2024, then dropped by 7.88% to -$204.2 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Enterprise Value are -$204.2 million (Q3 2025), -$251.2 million (Q2 2025), and -$293.4 million (Q1 2025).